Vor Biopharma Inc. Segments Disclosure
15. Segments
The Company operates and manages its business as one reportable and operating segment, centered around the commercial development of its product candidates. The Company’s chief operating decision maker (“CODM”) is the (“CEO”).
The Company’s CODM reviews consolidated operating results, manages the business on a consolidated basis and utilizes from the consolidated statements of operations and comprehensive loss to make decisions about allocating resources and assessing performance for the entire Company. Consolidated net loss is also used to monitor budget to actual results. The CODM is additionally regularly provided with more detailed expense information at the program level.
The following table is a summary of the segment profit or loss, including significant segment expenses (in thousands):
|
|
Year ended December 31, |
|
|||||
|
|
2024 |
|
|
2023 |
|
||
Segment expenses: |
|
|
|
|
|
|
||
Trem-cel(a) |
|
$ |
18,905 |
|
|
$ |
13,477 |
|
VCAR33(a) |
|
|
8,930 |
|
|
|
8,434 |
|
Other research and development(a) |
|
|
12,608 |
|
|
|
24,427 |
|
Salaries and benefits |
|
|
44,165 |
|
|
|
38,193 |
|
General corporate activities |
|
|
19,856 |
|
|
|
23,123 |
|
Other segment items(b) |
|
|
12,450 |
|
|
|
10,209 |
|
Segment expenses: |
|
|
116,914 |
|
|
|
117,863 |
|
Segment net loss |
|
|
(116,914 |
) |
|
|
(117,863 |
) |
(a) Includes only external research and development expenditures.
(b) Other segment items are primarily comprised of taxes, interest income on marketable securities and certain non-cash expenses such as stock-based compensation, depreciation expense, and non-cash lease expense.
The measure of segment assets is reported on the consolidated balance sheet as total assets. The CODM additionally reviews cash, cash equivalents and marketable securities when reviewing segment assets. As of December 31, 2024, the Company’s cash, cash equivalents and marketable securities were $91.9 million. The Company does not provide its CODM with any more detailed segment asset information than what is included on the Company’s consolidated balance sheets.
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.